Intra Cellular Therapies reported $-72662000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US $ -113.02M 68.36M
ALKERMES ALKS:US -26585000 28.97M
Aptinyx Inc APTX:US $ -19379000 207K
Biocryst Pharmaceuticals BCRX:US $ -49.96M 53.62M
Biogen BIIB:US $ 610.7M 23.6M
Bristol Myers Squibb BMY:US $ 2553M 90M
Cytokinetics CYTK:US $ -80.55M 58.85M
Esperion Therapeutics ESPR:US $ -42989000 12.64M
Gilead Sciences GILD:US $ 197M 743M
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Intra Cellular Therapies ITCI:US $ -72.66M 13.34M
JAZZ PHA JAZZ:US $ 87.55M 38.17M
Johnson & Johnson JNJ:US $ 5862M 1026M
Marinus Pharmaceuticals MRNS:US $ -16.71M 10.4M
Minerva Neurosciences NERV:US $ -7.99M 13.39M
Nektar Therapeutics NKTR:US $ -116.56M 3.65M
Neurocrine Biosciences NBIX:US $ 3.1M 39.4M
Novartis NVS:US $ 2852M 290M
Prothena PRTA:US -37944000 4.85M
Supernus Pharmaceuticals SUPN:US $ 1.97M 4.13M
United Therapeutics UTHR:US $ 286.3M 116.5M
Vanda Pharmaceuticals VNDA:US $ -7.67M 16.3M